Literature DB >> 21126312

Relaxin-3/insulin-like peptide 7, a neuropeptide involved in the stress response and food intake.

Masaki Tanaka1.   

Abstract

Relaxin-3, also known as insulin-like peptide-7, is a newly-identified peptide of the insulin superfamily. All members of this superfamily have a similar structure, which consists of two subunits (A-chain and B-chain) linked by disulfide bonds. Relaxin-3 is so named because it has a motif that can interact with the relaxin receptor. By contrast to other relaxins, relaxin-3 is mainly expressed in the brain and testis. In rodent brain, anatomical studies have revealed its predominant expression in neurons of the nucleus incertus of the dorsal pons, and a few other regions of the brainstem. On the other hand, relaxin-3-expressing nerve fibers and the relaxin-3 receptors, RXFP3 and RXFP1, are widely distributed in the forebrain, with the hypothalamus being one of the most densely-innervated regions. Therefore, relaxin-3 is considered to exert various actions through its ligand-receptor system. This minireview describes the expression of relaxin-3 in the brain, as well as its functions in the hypothalamus, including the stress response and food intake.
© 2010 The Author Journal compilation © 2010 FEBS.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21126312     DOI: 10.1111/j.1742-4658.2010.07931.x

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  10 in total

Review 1.  The Relaxin-3 Receptor, RXFP3, Is a Modulator of Aging-Related Disease.

Authors:  Hanne Leysen; Deborah Walter; Lore Clauwaert; Lieselot Hellemans; Jaana van Gastel; Lakshmi Vasudevan; Bronwen Martin; Stuart Maudsley
Journal:  Int J Mol Sci       Date:  2022-04-15       Impact factor: 6.208

2.  Dexmedetomidine alleviates postoperative cognitive dysfunction by inhibiting neuron excitation in aged rats.

Authors:  Bo Xiong; Qiqing Shi; Hao Fang
Journal:  Am J Transl Res       Date:  2016-01-15       Impact factor: 4.060

3.  The impact of apelin and relaxin plasma levels in masked hypertension and white coat hypertension.

Authors:  Elias Sanidas; Kostas Tsakalis; Dimitrios P Papadopoulos; Kanella Zerva; Maria Velliou; Despoina Perrea; Marina Mantzourani; Dimitrios Iliopoulos; John Barbetseas
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-12-07       Impact factor: 3.738

4.  Silencing relaxin-3 in nucleus incertus of adult rodents: a viral vector-based approach to investigate neuropeptide function.

Authors:  Gabrielle E Callander; Sherie Ma; Despina E Ganella; Verena C Wimmer; Andrew L Gundlach; Walter G Thomas; Ross A D Bathgate
Journal:  PLoS One       Date:  2012-08-02       Impact factor: 3.240

5.  Synthesis of fluorescent analogs of relaxin family peptides and their preliminary in vitro and in vivo characterization.

Authors:  Linda J Chan; Craig M Smith; Berenice E Chua; Feng Lin; Ross A D Bathgate; Frances Separovic; Andrew L Gundlach; Mohammed Akhter Hossain; John D Wade
Journal:  Front Chem       Date:  2013-12-06       Impact factor: 5.221

Review 6.  Relaxin-3/RXFP3 networks: an emerging target for the treatment of depression and other neuropsychiatric diseases?

Authors:  Craig M Smith; Andrew W Walker; Ihaia T Hosken; Berenice E Chua; Cary Zhang; Mouna Haidar; Andrew L Gundlach
Journal:  Front Pharmacol       Date:  2014-03-21       Impact factor: 5.810

7.  Effects of chronic silencing of relaxin-3 production in nucleus incertus neurons on food intake, body weight, anxiety-like behaviour and limbic brain activity in female rats.

Authors:  Camila de Ávila; Sandrine Chometton; Sherie Ma; Lola Torz Pedersen; Elena Timofeeva; Carlo Cifani; Andrew L Gundlach
Journal:  Psychopharmacology (Berl)       Date:  2020-01-03       Impact factor: 4.530

8.  Altered relaxin family receptors RXFP1 and RXFP3 in the neocortex of depressed Alzheimer's disease patients.

Authors:  Jasinda H Lee; Shu Qing Koh; Simone Guadagna; Paul T Francis; Margaret M Esiri; Christopher P Chen; Peter T-H Wong; Gavin S Dawe; Mitchell K P Lai
Journal:  Psychopharmacology (Berl)       Date:  2015-11-06       Impact factor: 4.530

9.  Apelin and relaxin plasma levels in young healthy offspring of patients with essential hypertension.

Authors:  Dimitris P Papadopoulos; Thomas Makris; Despina Perrea; Kannelina Zerva; Costas Tsioufis; Charles Faselis; Vasilios Papademetriou
Journal:  J Clin Hypertens (Greenwich)       Date:  2014-02-20       Impact factor: 3.738

10.  Masked hypertension and atherogenesis: the impact of apelin and relaxin plasma levels.

Authors:  Dimitris P Papadopoulos; Iordanis Mourouzis; Charles Faselis; Despina Perrea; Thomas Makris; Costas Tsioufis; Vasilios Papademetriou
Journal:  J Clin Hypertens (Greenwich)       Date:  2013-02-12       Impact factor: 3.738

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.